Utilización de los anticoagulantes orales de acción directa en Atención Primaria de España. Posicionamiento de SEMERGEN ante la situación actual

  1. J.L. Llisterri Caro 3
  2. S. Cinza-Sanjurjo 4
  3. J. Polo Garcia 1
  4. M.A. Prieto Díaz 2
  1. 1 Centro de Salud Casar de Cáceres, Casar de Cáceres, Cáceres, España
  2. 2 Centro de Salud Vallobín-La Florida, Oviedo, España
  3. 3 Fundación de Investigación SEMERGEN, Madrid, España
  4. 4 Centro de Salud Porto do Son, Porto do Son, A Coruña, España
Mostrar afiliacións +
Revista:
Semergen: revista española de medicina de familia

ISSN: 1138-3593

Ano de publicación: 2019

Número: 6

Páxinas: 413-429

Tipo: Artigo

DOI: 10.1016/J.SEMERG.2019.06.002 DIALNET GOOGLE SCHOLAR

Outras publicacións en: Semergen: revista española de medicina de familia

Resumo

The direct-acting oral anticoagulants (DOACs) are drugs that have been shown to have a safety profile superior to the vitamin K antagonists (VKA). The prescribing of DOACs in Spain is subject to approval in the form of an inspection visa. This sets out the clinical conditions defined in the Spanish Medicines Agency Therapeutic Positioning Report (TPR) of 2013, updated in 2016. These recommendations do not coincide with those of the European Cardiology Society (2016), restricting the use of DOACs to a second-line treatment in the majority of cases. Furthermore, this TPR is applied differently in the Regional Autonomous Communities and even in different health areas. This leads to a wide variation in the prescribing conditions, causing territorial inequalities in accessibility to these drugs by patients. The removal of the visa, and the appropriateness of the prescription to the recommendations of the Clinical Practice guidelines are key aspects to neutralise the current administrative and clinical barriers for the efficient use of DOACs in Primary Care. SEMERGEN supports the boosting of the clinical training and alliance with the patients in order to promote awareness and knowledge of atrial fibrillation.

Referencias bibliográficas

  • J.L. Llisterri, V. Pallarés, J. Polo, M.A. Prieto Posicionamiento de SEMERGEN sobre la utilización de los anticoagulantes orales de acción directa Madrid (2017) Disponible en: https://www.semergen.es/resources/files/biblioteca/guiaClinicas/Posicionamiento%20ACODs%20SEMERGEN.pdf Google Scholar
  • L. Cea-Calvo, J. Redón, J.V. Lozano, C. Fernández-Pérez, J.C. Martí-Canales, J.L. Llisterri, et al. Prevalencia de fibrilación auricular en la población española de 60 o más años de edad. Estudio PREV-ICTUS Rev Esp Cardiol., 60 (2007), pp. 616-624 ArticleDownload PDFCrossRefView Record in ScopusGoogle Scholar
  • P. Kirchhof, S. Benussi, D. Kotecha, A. Ahlsson, D. Atar, B. Casadei, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS Eur Heart J., 37 (2016), pp. 2893-2962 CrossRefView Record in ScopusGoogle Scholar
  • J. Masjuán, J. Álvarez-Sabín, M. Blanco, A. de Felipe, A. Gil-Núñez, J. Gállego-Culleré, et al. Manejo actual del tratamiento antitrombótico en pacientes con fibrilación auricular no valvular y antecedentes de ictus o ataque isquémico transitorio Rev Neurol., 59 (2014), pp. 25-36 View Record in ScopusGoogle Scholar
  • D. Pastori, P. Pignatelli, F. Angelico, A. Farcomeni, M. del Ben, T. Vicario, et al. Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: Relation to atherosclerotic risk factors Chest., 147 (2015), pp. 1644-1650 ArticleDownload PDFCrossRefView Record in ScopusGoogle Scholar
  • H.J. Lin, P.A. Wolf, M. Kelly-Hayes, A.S. Beiser, C.S. Kase, E.J. Benjamin, et al. Stroke severity in atrial fibrillation. The Framingham Study Stroke., 27 (1996), pp. 1760-1764 View Record in ScopusGoogle Scholar
  • F. Andrés-Nogales, J. Vivancos Mora, F.J. Barriga Hernández, F. Díaz Otero, L. Izquierdo Esteban, M.A. Ortega-Casarrubios, et al. Utilización de recursos sanitarios y costes asociados al manejo de los pacientes con infarto cerebral cardioembólico agudo en la Comunidad de Madrid: Estudio CODICE Neurologia., 30 (2015), pp. 536-544 Google Scholar
  • J. Álvarez-Sabín, J. Mar, J. Oliva, J. Masjuan, V. Becerra, C. Aleix, et al. Costes socioeconómicos del ictus en España: Estudio «CONOCES» Gac Sanit., 25 Espec Congr (2011), pp. 1-2 View Record in ScopusGoogle Scholar
  • C. Sánchez Impacto sociosanitario de las enfermedades neurológicas en España. Informe FEEN Fundación Española de Enfermedades Neurológicas, Madrid (2006) Google Scholar
  • D. Berti, J.M. Hendriks, A. Brandes, C. Deaton, H.J. Crijns, A.J. Camm, et al. A proposal for interdisciplinary, nurse-coordinated atrial fibrillation expert programmes as a way to structure daily practice Eur Heart J., 34 (2013), pp. 2725-2730 CrossRefView Record in ScopusGoogle Scholar
  • S. Stewart, J. Ball, J.D. Horowitz, T.H. Marwick, G. Mahadevan, C. Wong, et al. Standard versus atrial fibrillation-specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial Lancet., 385 (2015), pp. 775-784 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • J.M. Hendriks, R. de Wit, H.J. Crijns, H.J. Vrijhoef, M.H. Prins, R. Pisters, et al. Nurse-led care vs. usual care for patients with atrial fibrillation: Results of a randomized trial of integrated chronic care vs Routine clinical care in ambulatory patients with atrial fibrillation Eur Heart J., 33 (2012), pp. 2692-2699 CrossRefView Record in ScopusGoogle Scholar
  • J. Hendriks, F. Tomini, T. van Asselt, H. Crijns, H. Vrijhoef Cost-effectiveness of especialized atrial fibrillation clinic vs. usual care in patients with atrial fibrillation Europace., 15 (2013), pp. 1128-1135 CrossRefView Record in ScopusGoogle Scholar
  • G.Y. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, H.J. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation Chest., 137 (2010), pp. 263-272 ArticleDownload PDFCrossRefView Record in ScopusGoogle Scholar
  • J.B. Olesen, C. Torp-Pedersen, M.L. Hansen, G. Lip The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: A nationwide cohort study Thromb Haemost., 107 (2012), pp. 1172-1179 CrossRefView Record in ScopusGoogle Scholar
  • R. Pisters, D.A. Lane, R. Nieuwlaat, C.B. de Vos, H.J. Crijns, G.Y. Lip A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey Chest., 138 (2010), pp. 1093-1100 ArticleDownload PDFCrossRefView Record in ScopusGoogle Scholar
  • B.F. Gage, Y. Yan, P.E. Milligan, A.D. Waterman, R. Culverhouse, M.W. Rich, et al. Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF) Am Heart J., 151 (2006), pp. 713-719 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • M.C. Fang, A.S. Go, Y. Chang, L.H. Borowsky, N.K. Pomernacki, N. Udaltsova, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study J Am Coll Cardiol., 58 (2011), pp. 395-401 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • L. Friberg, M. Rosenqvist, G.Y. Lip Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: The Swedish Atrial Fibrillation cohort study Eur Heart J., 33 (2012), pp. 1500-1510 CrossRefView Record in ScopusGoogle Scholar
  • Z. Hijazi, J. Oldgren, J. Lindback, J.H. Alexander, S.J. Connolly, J.W. Eikelboom, et al. ARISTOTLE and RE-LY Investigators The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: A derivation and validation study Lancet., 387 (2016), pp. 2302-2311 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • R.G. Hart, L.A. Pearce, M.I. Aguilar Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med., 146 (2007), pp. 857-867 CrossRefView Record in ScopusGoogle Scholar
  • J. Mant, F.D. Hobbs, K. Fletcher, A. Roalfe, D. Fitzmaurice, G.Y. Lip, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomised controlled trial Lancet, 370 (2007), pp. 493-503 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • V. Barrios, C. Escobar, L. Prieto, J.M. Lobos, J. Polo, D. Vargas Control de la anticoagulación con warfarina o acenocumarol en España. ¿Hay diferencias? Rev Esp Cardiol., 68 (2015), pp. 1181-1182 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • V. Barrios, C. Escobar, L. Prieto, J. Osorio, J. Polo, J.M. Lobos, et al. Control de la anticoagulación en pacientes con fibrilación auricular no valvular asistidos en atención primaria en España. Estudio PAULA Rev Esp Cardiol., 68 (2015), pp. 769-776 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • V. Barrios, C. Escobar, A. Calderón, G.C. Rodríguez Roca, J.L. Llisterri, J. Polo García Uso del tratamiento antitrombótico según la escala CHA2DS2-VASc en los pacientes con fibrilación auricular en atención primaria Rev Esp Cardiol., 67 (2014), pp. 150-151 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • C.T. Ruff, R.P. Giugliano, E. Braunwald, E.B. Hoffman, N. Deenadayalu, M.D. Ezekowitz, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials Lancet., 383 (2014), pp. 955-962 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, et al., RE-LY Steering Committee and Investigatros Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med., 361 (2009), pp. 1139-1151 View Record in ScopusGoogle Scholar
  • M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, W. Hacke, et al., ROCKET AF Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med., 365 (2011), pp. 883-891 View Record in ScopusGoogle Scholar
  • C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, M. Hanna, et al., ARISTOTLE Committees and Investigators Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med., 365 (2011), pp. 981-992 CrossRefView Record in ScopusGoogle Scholar
  • R.P. Giuliano, C.T. Ruff, E. Braunwald, S.A. Murphy, S.D. Wiviott, J.L. Halperin, et al., ENGAGE AF-TIMI 48 Investigators Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med., 369 (2013), pp. 2093-2104 Google Scholar
  • F. Laliberte, M. Cloutier, W.W. Nelson, C.I. Coleman, D. Pilon, W.H. Olson, et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients Curr Med Res Opin., 30 (2014), pp. 1317-1325 CrossRefView Record in ScopusGoogle Scholar
  • D.J. Graham, M.E. Reichman, M. Wernecke, R. Zhang, M.R. Southworth, M. Levenson, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation Circulation., 131 (2015), pp. 157-164 View Record in ScopusGoogle Scholar
  • C.I. Coleman, M. Antz, B. Ehlken, T. Evers REal-LIfe evidence of stroke prevention in patients with atrial fibrillation—The RELIEF study Int J Cardiol., 203 (2016), pp. 882-884 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • X.S. Li, S. Deitelzweig, A. Keshishian, M. Hamilton, R. Horblyuk, K. Gupta, et al. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice. A propensity-matched analysis of 76,940 patients Thromb Haemost., 117 (2017), pp. 1072-1082 CrossRefView Record in ScopusGoogle Scholar
  • A. Dukanovic, L. Staerk, E.L. Fosbol, C. Sindet-Pedersen, A.N. Bonde, A.G. Lorentzen, et al. Dabigatran, rivaroxaban, and apixaban versus vitamin K antagonists for atrial fibrillation patients at low to intermediate stroke risk: A Danish nationwide cohort study. 2017 European Society of Cardiology Congress, Barcelona, 26-30 August 2017. Abstract 3596 Eur Heart J., 38 (Suppl) (2017), p. 770 View Record in ScopusGoogle Scholar
  • X. Yao, N.S. Abraham, L.R. Sangaralingham, M.F. Bellolio, R.D. McBane, N.D. Shah, et al. Effectiveness and safety of dabigatran rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation J Am Heart Assoc, 5 (2016), p. e250037 Google Scholar
  • T.B. Larsen, F. Skjøth, P.B. Nielsen, J.N. Kjældgaard, G.Y. Lip Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: Propensity weighted nationwide cohort study BMJ., 353 (2016), p. i3189 CrossRefGoogle Scholar
  • P.B. Nielsen, F. Skjøth, M. Søgaard, J.N. Kjældgaard, G.Y. Lip, T.B. Larsen Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: Propensity weighted nationwide cohort study BMJ., 356 (2017), p. j510 CrossRefView Record in ScopusGoogle Scholar
  • C.I. Coleman, W.F. Peacock, T.J. Bunz, M.J. Alberts Effectiveness and safety of apixabán, dabigatran, and rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and previous stroke or transient ischemic attack Stroke, 48 (2017), pp. 2142-2149 View Record in ScopusGoogle Scholar
  • A. Amin, A. Keshishian, J. Trocio, O. Dina, H. Le, L. Rosenblatt, et al. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population Curr Med Res Opin., 33 (2017), pp. 1595-1604 CrossRefView Record in ScopusGoogle Scholar
  • G.Y.H. Lip, F. Skjøth, P.B. Nielsen, J.N. Kjældgaard, T.B. Larsen Effectiveness and safety of standard-dose nonvitamin K antagonist oral anticoagulants and warfarin among patients with atrial fibrillation with a single stroke risk factor: A nationwide cohort study JAMA Cardiol., 2 (2017), pp. 872-881 CrossRefView Record in ScopusGoogle Scholar
  • Y. Vinogradova, C. Coupland, T. Hill, J. Hippisley-Cox Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: Cohort study in primary care BMJ., 362 (2018), p. k2505 CrossRefView Record in ScopusGoogle Scholar
  • G.Y.H. Lip, A. Keshishian, X. Li, M. Hamilton, C. Masseria, K. Gupta, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients Stroke., 49 (2018), pp. 2933-2944 CrossRefView Record in ScopusGoogle Scholar
  • T. Forslund, B. Wettermark, M. Andersen, P. Hjemdahl Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: A population-based cohort study Europace., 20 (2018), pp. 420-428 View Record in ScopusGoogle Scholar
  • C.I. Coleman, M. Antz, K. Bowrin, T. Evers, E.P. Simard, H. Bonnemeier, et al. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: The REVISIT-US study Curr Med Res Opin., 32 (2016), pp. 2047-2053 CrossRefView Record in ScopusGoogle Scholar
  • M.H. Ellis, T. Neuman, H. Bitterman, S.G. Dotan, A. Hammerman, E. Battat, et al. Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: A retrospective population-based cohort study Eur J Intern Med., 33 (2016), pp. 55-59 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • D.J. Graham, M.E. Reichman, M. Wernecke, Y.H. Hsueh, R. Izem, M.R. Southworth, et al. Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation JAMA Intern Med., 176 (2016), pp. 1662-1671 CrossRefView Record in ScopusGoogle Scholar
  • X. Yao, N.S. Abraham, L.R. Sangaralingham, M.F. Bellolio, R.D. McBane, N.D. Shah, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation J Am Heart Assoc., 5 (2016), p. e003725 CrossRefView Record in ScopusGoogle Scholar
  • G.Y.H. Lip, A. Keshishian, S. Kamble, X. Pan, J. Mardekian, R. Horblyuk, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis Thromb Haemost., 116 (2016), pp. 975-986 CrossRefView Record in ScopusGoogle Scholar
  • T.B. Larsen, F. Skjoth, P.B. Nielsen, J.N. Kjaldgaard, G.Y. Lip Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: Propensity weighted nationwide cohort study BMJ., 353 (2016), p. i3189 CrossRefGoogle Scholar
  • P.A. Noseworthy, X. Yao, N.S. Abraham, L.R. Sangaralingham, R.D. McBane, N.D. Shah Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation Chest., 150 (2016), pp. 1302-1312 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • L. Staerk, T.A.G. Gerds, G.Y.H.L. Lip, B.O. Ozenne, A.N.B. Bonde, M.L. Lamberts, et al. Standard and reduced doses of dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation: A nationwide cohort study. 2017 European Society of Cardiology Congress, Barcelona, 26-30 August 2017. Abstract 2049 Eur Heart J., 38 (Suppl) (2017), p. 416 View Record in ScopusGoogle Scholar
  • F.L. Norby, L.G.S. Bengtson, P.L. Lutsey, L.Y. Chen, R.F. MacLehose, A.M. Chamberlain, et al. Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation BMC Cardiovasc Disord., 17 (2017), p. 238 View Record in ScopusGoogle Scholar
  • G. Adeboyeje, G. Sylwestrzak, J.J. Barron, J. White, A. Rosenberg, J. Abarca, et al. Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation J Manag Care Spec Pharm., 23 (2017), pp. 968-978 CrossRefView Record in ScopusGoogle Scholar
  • S. Deitelzweig, X. Luo, K. Gupta, J. Trocio, J. Mardekian, T. Curtice, et al. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients Curr Med Res Opin., 33 (2017), pp. 1745-1754 CrossRefView Record in ScopusGoogle Scholar
  • I. Hernandez, Y. Zhang, S. Saba Comparison of the effectiveness and safety of apixaban, dabigatran, rivaroxaban, and warfarin in newly diagnosed atrial fibrillation Am J Cardiol., 120 (2017), pp. 1813-1819 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • P.G. Tepper, J. Mardekian, C. Masseria, H. Phatak, S. Kamble, Y. Abdulsattar, et al. Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban PLoS ONE., 13 (2018), p. e0205989 CrossRefView Record in ScopusGoogle Scholar
  • K. Gupta, J. Trocio, A. Keshishian, Q. Zhang, O. Dina, J. Mardekian, et al. Real-world comparative effectiveness, safety, and health care costs of oral anticoagulants in nonvalvular atrial fibrillation patients in the U.S. Department of Defense population J Manag Care Spec Pharm., 24 (2018), pp. 1116-1127 CrossRefGoogle Scholar
  • A. Amin, A. Keshishian, J. Trocio, O. Dina, H. Le, L. Rosenblatt, et al. A real-world observational study of hospitalization and health care costs among nonvalvular atrial fibrillation patients prescribed oral anticoagulants in the U.S. Medicare population J Manag Care Spec Pharm., 24 (2018), pp. 911-920 CrossRefView Record in ScopusGoogle Scholar
  • A. Amin, A. Keshishian, L. Vo, Q. Zhang, O. Dina, C. Patel, et al. Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan J Med Econ., 21 (2018), pp. 244-253 CrossRefView Record in ScopusGoogle Scholar
  • L. Staerk, T.A. Gerds, G.Y.H. Lip, B. Ozenne, A.N. Bonde, M. Lamberts, et al. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: A nationwide cohort study J Intern Med., 283 (2018), pp. 45-55 CrossRefView Record in ScopusGoogle Scholar
  • A.M. Gilligan, J. Franchino-Elder, X. Song, C. Wang, C. Henriques, A. Sainski-Nguyen, et al. Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin Expert Rev Pharmacoecon Outcomes Res., 19 (2019), pp. 203-212 CrossRefView Record in ScopusGoogle Scholar
  • D.J. Graham, E. Baro, R. Zhang, J. Liao, M. Wernecke, M.E. Reichman, et al. Comparative stroke, bleeding, and mortality risks in older Medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation Am J Med., 132 (2019), pp. 596-604 View Record in ScopusGoogle Scholar
  • M. Anguita-Sánchez, V. Bertomeu-Martínez, M. Ruiz-Ortiz, A. Cequier-Fillat, I. Roldán-Rabadán, J. Muñiz-García, et al., en representación de los investigadores del Estudio FANTASIIA Anticoagulantes orales directos frente a antagonistas de la vitamina K en pacientes del «mundo real» con fibrilación auricular no valvular. Estudio FANTASIIA Rev Esp Cardiol. (2019), 10.1016/j.recesp.2019.02.003 Google Scholar
  • J. Polo García, V. Barrios Alonso, C. Escobar Cervantes, L. Prieto Valiente, J.M. Lobos Bejarano, D. Vargas Ortega, et al. Control de la anticoagulación en pacientes con fibrilación auricular no valvular en práctica clínica de atención primaria en las diferentes comunidades autónomas. Estudio PAULA Semergen., 43 (2017), pp. 207-215 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • J. Polo, D. Vargas, F. Formiga, I. Unzueta, S. Fernández, J. Chaves Profiling of patients with non-valvular atrial fibrillation and moderate-to-high risk of stroke not receiving oral anticoagulation in Spain Semergen. (2018), 10.1016/j.semerg.2018.10.005 Google Scholar
  • S. Cinza-Sanjurjo, D. Rey-Aldana, E. Gestal-Pereira, C. Calvo-Gómez Evaluación del grado de anticoagulación de pacientes con fibrilación auricular en el ámbito de atención primaria de Galicia. Estudio ANFAGAL Rev Esp Cardiol., 68 (2015), pp. 753-760 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • M. Anguita Sánchez, V. Bertomeu Martínez, Á. Cequier Fillat Calidad de la anticoagulación con antagonistas de la vitamina K en España: prevalencia de mal control y factores asociados Rev Esp Cardiol., 68 (2015), pp. 761-768 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • J.M. Lobos-Bejarano, J.C. del Castillo-Rodríguez, A. Mena-González, J.J. Alemán-Sánchez, J. Cabrera, G. Barón-Esquivias Características de los pacientes y abordaje terapéutico de la fibrilación auricular en atención primaria en España: Estudio FIATE Med Clin (Barc)., 141 (2013), pp. 279-286 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • V. Barrios, C. Escobar, J.M. Lobos, J. Polo, D. Vargas Uso de los anticoagulantes orales de acción directa en atención primaria: Estudio ACTUA Semergen., 43 (2017), pp. 477-485 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • A. Troncoso, E. Diogène Dabigatran and rivaroxaban prescription for atrial fibrillation in Catalonia, Spain: The need to manage the introduction of new drugs Eur J Clin Pharmacol., 70 (2014), pp. 249-250 CrossRefView Record in ScopusGoogle Scholar
  • J.L. Segú Acceso a los anticoagulantes de acción directa en España Rev Esp Cardiol Supl., 16A (2016), pp. 55-59 View Record in ScopusGoogle Scholar
  • A.M. Urbaniak, B.O. Strøm, R. Krontveit, K.H. Svanqvist Prescription patterns of non-vitamin K. Oral anticoagulants across indications and factors associated with their increased prescribing in atrial fibrillation between 2012-2015: A study from the Norwegian Prescription Database Drugs Aging., 34 (2017), pp. 635-645 CrossRefView Record in ScopusGoogle Scholar
  • J.I. Weitz, W. Semchuk, A.G. Turpie, W.D. Fisher, C. Kong, A. Ciaccia, et al. Trends in prescribing oral anticoagulants in Canada, 2008-2014 Clin Ther., 37 (2015), pp. 2506-2514.e4 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • S.Y. Loo, S. dell’Aniello, L. Huiart, C. Renoux Trends in the prescription of novel oral anticoagulants in UK primary care Br J Clin Pharmacol., 83 (2017), pp. 2096-2106 CrossRefView Record in ScopusGoogle Scholar
  • M.B. Protty, J. Hayes Dawn of the direct-acting oral anticoagulants: Trends in oral anticoagulant prescribing in Wales 2009-2015 J Clin Pharm Ther., 42 (2017), pp. 132-134 CrossRefView Record in ScopusGoogle Scholar
  • M. de la Figuera, S. Cinza, N. Marín, I. Egocheaga, M.A. Prieto, en nombre de los investigadores del estudio SILVER-AP Perfil clínico de pacientes con fibrilación auricular tratados con anticoagulantes orales de acción directa atendidos en atención primaria. Estudio SILVER-AP Aten Primaria., 50 (2018), pp. 359-367 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • J. Precioso, M. Larré, F.M. Navarro, Y.A. Silvero, L. Garrido, J.L. Llisterri Grado de control y cumplimiento terapéutico de la anticoagulación con acenocumarol en atención primaria Semergen., 42 (2016), pp. 363-369 Google Scholar
  • M. De la Figuera, M.A. Prieto, N. Marín, I. Egocheaga, S. Cinza Diferencias en el manejo de los pacientes con fibrilación auricular según inicie el tratamiento con anticoagulantes orales de acción directa el médico de atención primaria o el especialista. Estudios SILVER-AP y BRONCE-AP Semergen., 44 (2018), pp. 323-334 ArticleDownload PDFGoogle Scholar
  • J.M. Lobos, J. Polo, D. Vargas El médico de familia ante las barreras en la prescripción de los nuevos anticoagulantes orales: heterogeneidad, inequidad y confusión. Posicionamiento de las Sociedades Científicas de Atención Primaria en España Semergen., 46 (2014), pp. 1-3 View Record in ScopusGoogle Scholar
  • I. Roldán, F. Marín En el camino de un mejor uso de los anticoagulantes en la fibrilación auricular no valvular. Propuesta de modificación del posicionamiento terapéutico UT/V4/23122013 Rev Esp Cardiol., 69 (2016), pp. 551-553 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • J. Erviti Incertidumbres sobre los nuevos anticoagulantes orales en fibrilación auricular. Irregularidades y lagunas en su autorización Boletín de Información Farmacoterapéutica de Navarra., 24 (2016), pp. 1-12 View Record in ScopusGoogle Scholar
  • C.A. Garmendia, L. Nassar Gorra, A.L. Rodriguez, M.J. Trepka, E. Veledar, P. Madhivanan Evaluation of the inclusion of studies identified by the FDA as having falsified data in the results of meta-analyses: The example of the apixaban trials JAMA Intern Med. (2019), 10.1001/jamainternmed.2018.7661 Google Scholar
  • V. Roldán, S. Cancio, J. Gálvez, M. Valdés, V. Vicente, F. Marín, et al. The SAMe-TT2R2 score predicts poor anticoagulation in atrial fibrillation patients initiating vitamin K antagonists: A prospective “real world” inception cohort study Am J Med., 128 (2015), pp. 1237-1243 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • M. Anguita, A. Dávalos, E. López de Sa, J. Mateo, M. Monreal, J. Oliva, et al. Anticoagulantes orales directos en la fibrilación auricular: cómo mejorar su uso en España Semergen., 45 (2019), pp. 109-116 ArticleDownload PDFView Record in ScopusGoogle Scholar
Fonte de datos: Dialnet